Disclosure of Unlabeled Use and Investigational Product
This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will review the quality-of-life impact of geographic atrophy (GA) and examine current and emerging treatment approaches, including complement inhibitors and other pathways, such as neuroprotective agents and gene therapy. Discussion will include the rationale for various treatment approaches in GA and examine the safety and efficacy data from key clinical trials.
This activity is designed for an audience of ophthalmologists, optometrists, and other members of the healthcare team who treat patients with GA.
Upon completion of the educational activity, participants should be able to:
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at
ketrea@akhcme.com
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.00
AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AKH Inc., Advancing Knowledge in Healthcare designates this asynchronous activity for a maximum of 1.0 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by independent educational grants from Alcon, Genentech, Regenxbio, Tarsus, Théa, and Visus.
Name
Relationship
Commercial Interest
Nadia Waheed, MD, MPH (faculty)
Consultant
Nidek
Consultant
Zeiss
Consultant
Topcon (imaging research)
Consultant
Ocudyne
Consultant
Stealth
Consultant
Novartis
Consultant
Complement Therapeutics
Consultant
Johnson & Johnson Vision
Consultant
Saliogen
Consultant
Valitor
Consultant
Olix
Employee
AGTC
Andrew Moshfeghi, MD, MBA (faculty)
Consultant, Research
Regeneron
Consultant, Research
Genentech/Roche
Consultant, Research
Novartis
Consultant
Allergan
Consultant
Alimera
Consultant, Stock
Ocular Therapeutix
Consultant, Stock
Valitor
Consultant
OcuTerra
Consultant
Ainsly ltd; dba Waldo
Consultant
Pr3vent
Session Planners/Reviewers/Accreditors
Dorothy Caputo, MA, BSN, RN - VP, Healthcare
Continuing Education and Operations
N/A
Nothing to disclose
Michele Bielarski, RN (planner/reviewer)
N/A
Nothing to disclose
AKH Inc. Staff and Planners
N/A
Nothing to disclose
International Healthcare Media dba
International Healthcare Education Staff and
Planners
N/A
Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.
Emerging Treatments in Geographic Atrophy: Reason for Hope?
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.